Latest California Healthline Stories
Patients flocked to researcher who ignored usual patient protections, as university claimed ignorance.
The costs of using a new class of cancer treatments include far more than the drug’s sticker price.
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
“If it gets signed by this governor, it’s going to send shock waves throughout the country,” one legislator says. Pharma has spent $16.8 million to lobbying against this bill and other drug laws in California.
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Following a KHN and NPR investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.